IDEAYA Biosciences raises $300M in public-market common stock offering
What's the deal? Ideaya Biosciences, a precision medicine oncology company, is raising $300M through a spot secondary offering of common stock, re-offered at $27.00 per share. JPMorgan, Jefferies, TD Cowen, UBSDealroom has a profile for this one. Try Dealroom →, and Cantor FitzgeraldDealroom has a profile for this one. Try Dealroom → are acting as joint book-running managers for the deal.
Why now? The offering comes on the heels of several significant developments for the company. Ideaya recently launched a PRMT5 and pan-RAS collaboration with RocheDealroom has a profile for this one. Try Dealroom →, including a separate deal around its IDE892 programme. The company has also reported positive Phase 2/3 results for its darovasertib trial, strengthening its oncology pipeline story.
At least one analyst has reiterated a buy rating on the stock with a $62 price target — more than double the offering price — citing the company's strong pipeline and partnerships.
What could go wrong? The $27.00 re-offer price sits well below the analyst target, suggesting the market is pricing in significant risk. Secondary offerings can dilute existing shareholders, and biotech companies at this stage remain vulnerable to clinical trial setbacks or partnership complications.
The signal: Classified as a late-growth stage company by Dealroom, Ideaya's $300M raise underscores how precision oncology firms with validated clinical programmes and big-pharma partnerships — such as its recent PRMT5 and pan-RAS collaboration with Roche — can still command sizeable public-market capital. The participation of heavyweight institutional managers like UBS and Cantor Fitzgerald, both active corporate investors in their own right, suggests durable appetite for oncology assets even at a discounted offering price.
Read more: Business Insider
